A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
P169Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes
European Heart Journal
Lipid-lowering therapy: old faces and new issues 29 ing taken by 25.7% of patients with an indication; 47.3% of patients with MI or coronary revascularization were taking a statin compared with 40.4%, 33.8% and 18.9% with diabetes, LDL-C ≥190mg/dL and 10-year CVD risk ≥7.5% respectively (Table 1 ). In multivariable analysis and compared with patients with history of MI or coronary revascularization, those with diabetes, LDL-C ≥190 mg/dL, and 10-year CVD risk ≥7.5% were less likely to be takingdoi:10.1093/eurheartj/ehx501.p169 fatcat:4jxe6di7c5e6rhcjcnmup5kpuq